Key facts
- It has raised $10.6M; the latest was Later Stage VC ($10K) in Nov 2024.
- Notable investors include SBI Investment, Korea Investment Partners, Korea Development Bank, KB Securities, Kolon Investment — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for MEPSGEN
- ·The full record, as it builds
Funding rounds
No funding rounds for MEPSGEN are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About MEPSGEN
Developer of micro-engineered physiological systems designed to create human model-centered drugs. The company's systems carry out fundamental biological research in an environment equipped with an organ-level function of connected human tissues instead of in a traditional in-vitro experimental model using 2D cell culture, enabling researchers to further verify in a physiologically relevant environment to validate the discovery of new biological mechanisms.
- Sector
- Healthcare
- HQ
- Seoul, South Korea
- Founded
- 2019
- Employees
- 33
- Website
- mepsgen.com/
- Ownership
- Privately Held (backing)
MEPSGEN doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in MEPSGEN shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on MEPSGEN in its N-PORT filings yet. We sweep new filings monthly.